Antibodies

Antibodies is an open access journal on antibody and antigen science, published by MDPI.《Antibodies》是一份聚焦抗体与抗原科学的开放获取期刊，由 MDPI 出版。

It was launched in 2012, and it was set up to move a finding on antibodies toward an application as quickly as it can.该刊于 2012 年创办，其设立意在尽快把抗体方面的发现推向应用。

In the 2025 edition of the journal citation report it holds an impact factor of 3.3, and it stands in the third quartile of immunology.在 2025 年版期刊引证报告中，该刊的影响因子为 3.3，在免疫学类目列第三区。

Scope

• The journal takes antibodies and antigens as its subject, and it asks how a molecule of this kind is made and put to work.该刊以抗体与抗原为题材，追问这类分子如何被制造与投入使用。

• Antibody structure and function are named, and the journal carries work on how a chain is folded and what it binds.抗体的结构与功能被点名，该刊刊载链如何折叠、结合何物的工作。

• Antibody to antigen interaction is treated, and the journal admits work on how a pairing is measured.抗体与抗原的相互作用得到处理，该刊收载配对如何被测量的工作。

• Antibody manufacturing is named, and the journal takes work on how a line is run to make a therapeutic protein.抗体的生产被点名，该刊收载为制造治疗用蛋白而如何运行生产线的工作。

• Antibody engineering is treated, and the journal carries work on how a molecule is reshaped for a purpose.抗体工程得到处理，该刊刊载分子如何为某一目的被重塑的工作。

• Monoclonal antibodies are named, and the journal admits work on how a single clone is grown and harvested.单克隆抗体被点名，该刊收载单一克隆如何被培养与收获的工作。

• Recombinant antibodies are part of the remit, and the journal takes work on how such a molecule is expressed.重组抗体属于收稿范围，该刊收载此类分子如何被表达的工作。

• Human monoclonal antibodies are named as a special interest, and the journal carries work on a therapeutic that comes from a human sequence.人源单克隆抗体被点名为特别关注，该刊刊载源自人序列的治疗药物的相关工作。

• Immunoassays are treated, and the journal admits work on how a substance is detected through an antibody.免疫测定得到处理，该刊收载物质如何经抗体被检出的工作。

• Autoantigens are named, and the journal takes work on the molecules against which the body turns its own defences.自身抗原被点名，该刊收载身体以自身防御相对抗的分子方面的工作。

• Immunoregulatory molecules are treated, and the journal carries work on the signals that govern a humoral response.免疫调节分子得到处理，该刊刊载支配体液应答的信号方面的工作。

• Cancer immunotherapy is named, and the journal admits work on how a treatment is aimed through an antibody.癌症免疫治疗被点名，该刊收载治疗如何借抗体瞄准靶点的工作。

• Infectious disease and vaccine work is treated, and the journal takes work on how a response is measured after a vaccination.传染病与疫苗工作得到处理，该刊收载接种后应答如何被测量的工作。

• Diagnostic work is admitted, and the journal carries papers on how an antibody is used to read a specimen.诊断工作受到收载，该刊刊载抗体如何被用于判读标本的论文。

• Reviews, research articles and communications are all taken, and the journal sets out the structure each should follow.综述、研究论文与短讯均予收载，该刊列出各类应遵循的结构。

• The journal asks for full experimental detail, and it takes a contribution that reports a method as readily as one that reports a result.该刊要求完整的实验细节，报告方法的投稿与报告结果的投稿一并收载。

History

• The journal was launched in 2012, and its first issue appeared in that year.该刊于 2012 年创办，其首期于当年出版。

• It was set up by a publishing house in Switzerland, and it was issued as a quarterly from the start.该刊由瑞士的一家出版社设立，自始即以季刊发行。

• Its founding editor opened the title with an editorial on antibodies as the agents of a humoral response.其创始主编以一篇社论为该刊开篇，论抗体作为体液应答的执行者。

• Only one number is in use for the title, and the journal is published online rather than in print.该刊只使用一个刊号，以在线而非印刷形式出版。

• Four issues are gathered into a year, and the journal has kept that rhythm since it was founded.该刊每年汇集四期，自创办以来一直保持这一节奏。

• A volume is published for each year, and the series had reached volume 15 by 2026.该刊每年出版一卷，到 2026 年已出至第 15 卷。

• The title was indexed step by step, and it was taken first into a citation index and then into a biomedical database.该刊逐步被收录，先进入一个引文索引，继而进入一个生物医学数据库。

• Access was open from the start, and every article is free to read from the moment it appears.该刊自始即开放获取，每篇文章自出现那一刻起即可免费阅读。

• A publication charge applies to an accepted paper, and the journal points to the publisher's policy and to its waiver scheme.被录用的论文须缴纳出版费用，该刊指明出版方的政策与减免方案。

• Authors keep the copyright of their work, and every article is released under a licence that allows reuse with attribution.作者保留其作品的著作权，每篇文章以允许署名再用的许可发布。

• The impact figure has eased and then risen, standing at 3 for 2023 and reaching 3.3 in the 2025 edition.影响因子先回落而后上升，2023 年为 3，2025 年版为 3.3。

• Four sections divide the field, and each has its own editor for discovery, for therapeutics, for diagnostics or for humoral immunity.该刊以四个栏目划分领域，各有其编辑分别负责发现、治疗、诊断与体液免疫。

• Special collections are assembled around a subject, and the journal has gathered papers on such themes as autoimmune disease.该刊围绕某一题目编成专题合集，汇集诸如自身免疫病一类主题的论文。

Editors

• Arne Skerra of the Technical University of Munich is editor-in-chief, and his own field is the design of proteins that bind a chosen target.慕尼黑工业大学的（Arne Skerra）担任主编，其本人领域为结合选定靶点的蛋白质设计。

• A founding editor led the title in its early years, and he wrote on antibodies as the carriers of a humoral response.创始主编在该刊早年主持之，曾就抗体作为体液应答的载体撰文。

• Each of the four sections has an editor-in-chief of its own, and the journal names them beside the senior board.四个栏目各有一位自己的主编，该刊将其列于资深编委之侧。

• The board is international in its reach, and the journal draws its members from universities across several continents.编委会触角遍及国际，该刊从数个大洲的大学遴请成员。

• The journal sets out the classes of manuscript it takes, along with the length and structure each of them should follow.该刊列明所收稿件的类别，以及各类别应遵循的篇幅与结构。

• Each paper is sent to independent referees, and the review is anonymous on the side of the reviewer.每篇论文送交独立审稿人，评审在审稿人一侧为匿名。

• Authors must declare any competing interest, and the journal states its ethical requirements in full.作者必须声明任何利益冲突，该刊完整说明其伦理要求。

• Work that involves human or animal subjects is held to the usual standards, and the journal asks that approval be recorded.涉及人或动物的研究须达到惯常标准，该刊要求记录批准情况。

• A paper on a new reagent is asked to give its sequence and its characterisation, so that another laboratory can repeat it.论及新试剂的研究须给出其序列与表征，使另一实验室可以重复。

• Manuscripts are submitted through the publisher's system, and a supplementary file may carry a full set of calculations.稿件通过出版方的系统投递，补充文件可以承载整套计算。

• The journal is read by immunologists and by protein engineers, by clinicians and by biotechnologists, and it writes for all of them.该刊的读者既有免疫学家与蛋白质工程师，也有临床医生与生物技术研究者，它为这几类人写作。

• Work that carries a laboratory binding molecule toward a clinic is given room, and the journal asks what the carrying changes.把实验室结合分子带向临床的工作有篇幅可用，该刊追问这一带动改变了什么。

• Studies that report a negative result are taken, since a binder that failed to hold its target is worth recording.报告阴性结果的研究也在收载之列，因为未能结合其靶点的结合体同样值得记录。

• Work on a bispecific molecule appears among the subjects, and the journal carries papers on how one construct grips two targets.双特异性分子方面的工作列于选题之中，该刊刊载一种构建体如何抓住两个靶点的论文。

• Work on antibody stability is treated, and the journal admits papers on how a molecule is kept from clumping in storage.抗体稳定性方面的工作得到处理，该刊收载分子如何在储存中不被聚集的论文。

• The journal keeps its reviews distinct from its research articles, and a reader can tell from the rubric which is which.该刊把综述与研究论文区分开来，读者可从栏目看出何者为何者。

• Work on an antibody drug conjugate is named, and the journal carries papers on how a payload is attached and delivered.抗体偶联药物方面的工作被点名，该刊刊载载荷如何被连接与递送的论文。

• Work on a nanobody is treated, and the journal admits papers on how a single domain is made to bind.纳米抗体方面的工作得到处理，该刊收载单一结构域如何被做得结合的论文。

• Work on a point of care assay is named, and the journal asks what a test can show at the bedside.即时检验方面的工作被点名，该刊追问一项检测在床边能显示什么。

• Work that links a binding property to a treatment outcome is welcomed, and the journal carries papers on what the link promises.把结合性质与治疗结局相连的工作受到欢迎，该刊刊载这一联系寄予何种希望的工作。

• The journal follows the publisher's policy on research integrity, and it records corrections and withdrawals where they arise.该刊遵循出版方的研究诚信政策，出现更正与撤稿时予以记录。